Skip to main content
SpringerLink
Log in
Book cover

Atherosclerosis, Hypertension and Diabetes pp 301–315Cite as

Endothelins and Cardiovascular Disease in Diabetes

  • Chapter
  • First Online:

  • 184 Accesses

Part of the book series: Progress in Experimental Cardiology ((PREC,volume 8))

Abstract

Cardiovascular affection is a major cause of mortality and morbidity in the diabetic population. Secondary to hyperglycemia, several abnormal metabolic pathways may be activated in diabetes. Some of these pathways may lead to alteration of the endothelins (ETs). ETs, due to their diverse biological action, may act as an effector molecule in the pathogenesis of diabetes associated lesions in the heart and vasculature. This review will discuss the mechanisms and implication of ET alteration in the pathogenesis of cardiovascular complications of diabetes.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. A Report of the Congressionally-Established Diabetes Research Working Group. 1999. Conquering Diabetes: A Strategic Plan for the 21st Century, Bethesda, Md: National Institutes of Health Publication No. 99–4398.

    Google Scholar 

  2. Harris MI. 1998. Diabetes in America: epidemiology and scope of the problem, Diabetes Care 21:C11–C14.

    PubMed  Google Scholar 

  3. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. 1998–1994. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, Diabetes Care 21:518–524.

    Google Scholar 

  4. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997, 1998. Diabetes Care 21:296–309.

    Google Scholar 

  5. Epstein M, Sowers Jr. 1992. Diabetes mellitus and hypertension. Hypertension 19:403–418.

    Article  PubMed  CAS  Google Scholar 

  6. Hedblad B, Nilsson P, Janzon L, Berglund G. 2000. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 17:299–307.

    Article  PubMed  CAS  Google Scholar 

  7. Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM. 1988. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 62:665–669.

    Article  PubMed  CAS  Google Scholar 

  8. Lewinter MM. 1996. Diabetic cardiomyopathy: an overview. Coron Artery Dis 7:95–98.

    Article  PubMed  CAS  Google Scholar 

  9. International Diabetes Federation Triennial Report 1991–1994. 1994. IDF Brussels.

    Google Scholar 

  10. Nunoda S, Genda A, Sekiguchi M, Takeda R. 1985. Left ventricular endomyocardial biopsy findings in patients with essential hypertension and hypertrophic cardiomyopathy with special reference to the incidence of bizarre myocardial hypertrophy with disorganization and biopsy score. Heart Vessels 1:170–175.

    Article  PubMed  CAS  Google Scholar 

  11. Shehadeh A, Regan TJ. 1995. Cardiac consequences of diabetes mellitus, Clin. Cardiol 18:301–305.

    CAS  Google Scholar 

  12. Zhang WX, Chakrabarti S, Green DA, Sima AA. 1990. Diabetic autonomic neuropathy in BB rats and effect of ARI treatment on heart rate variability and vagus structure. Diabetes 39:613–618.

    Article  PubMed  CAS  Google Scholar 

  13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. 1998. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med: 229–234.

    Google Scholar 

  14. National Institute of Health, National Institute of Diabetes, Digestive and Kidney Disease. 1995. Diabetes in America 2nd edition, 449–456.

    Google Scholar 

  15. Schwartz SM. 1995. The intima. Soil for atherosclerosis and restenosis. Circ Res 77:445–465.

    Article  PubMed  CAS  Google Scholar 

  16. Yangisawa M, Kurihara H, Kimura S. 1988. A novel vasoconstrictor peptide produced by the vascular endothelial cells. Nature 332:411–415.

    Article  Google Scholar 

  17. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. 1989. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863–2867.

    Article  PubMed  CAS  Google Scholar 

  18. Takahashi M, Matsushita Y, Iijima Y, Tanzawa K. 1993. Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem 268:21394–21398.

    Google Scholar 

  19. Emoto N, Yanagisawa M. 1995. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270:15262–15268.

    Article  PubMed  CAS  Google Scholar 

  20. Shimada K, Takahashi M, Ikeda M, Tanzawa K. 1995. Identification and characterization of two isoforms of an endothelin-converting enzyme-1. FEBS Lett 371:140–144.

    Article  PubMed  CAS  Google Scholar 

  21. Valdenaire O, Rohrbacher E, Mattei MG. 1995. Organization of the gene encoding the human endothelin-converting enzyme (ECE-l). J Biol Chem 270:29794–29798.

    Article  PubMed  CAS  Google Scholar 

  22. Schweizer A, Valdenaire O, Nelbock P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG, Loffler BM. 1997. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J 328:871–877.

    PubMed  CAS  Google Scholar 

  23. Valdenaire O, Lepailleur-Enouf D, Egidy G, Thouard A, Barret A, Vranckx R, Tougard C, Michel JB. 1999. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. Eur J Biochem 264:341–349.

    Article  PubMed  CAS  Google Scholar 

  24. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. 1990. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730–732.

    Article  PubMed  CAS  Google Scholar 

  25. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. 1990. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348:732–735.

    Article  PubMed  CAS  Google Scholar 

  26. Bax WA, Aghai Z, van Tricht CL, Wasenaar C, Saxena PR. 1994. Different endothelin receptors invovled in endothelin-1- and sarafotoxin S6b-induced contractions of the human isolated coronary artery. Br J Pharmacol 113:1471–1479.

    Article  PubMed  CAS  Google Scholar 

  27. Clark KL, Pierre L. 1995. Characterization of endothelin receptors in rat renal artery in vitro. Br J Pharmacol 114:785–790.

    Article  PubMed  CAS  Google Scholar 

  28. Godfraind T. 1993. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol 110:1201–1205.

    Article  PubMed  CAS  Google Scholar 

  29. Eglazos A, Cucchi P, Patacchini R, Quartara L, Maggi CA, Mizrahi J. 1993. Differential effects of BQ-123 against endothelin-1 and endothelin-3 on the rat vas deferens: evidence of an atypical endothelin receptor. Br J Pharmacol 109:736–738.

    Article  Google Scholar 

  30. Ishikawa H, Haruno I, Harada Y, Yoshitomi T, Ishikawa S, Katori M. 1996. Pharmacological characterization of endothelin receptors in rabbit iris sphincter muscle: suggestion for the presence of atypical receptors. Curr Eye Res 15:73–78.

    Article  PubMed  CAS  Google Scholar 

  31. Riezebos J, Watts IS, Vallance PJ. 1994. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol 111:609–615.

    Article  PubMed  CAS  Google Scholar 

  32. Sumner MJ, Cannon TR, Mundin JW, White DG, Watts IS. 1992. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 107:858–860.

    Article  PubMed  CAS  Google Scholar 

  33. Warner TD, Allcock GH, Corder R, Vane JR. 1993. Use of endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol 110:777–782.

    Article  PubMed  CAS  Google Scholar 

  34. Warner TD, Allcock GH, Mickey EJ, Vane JR. 1993. Characterization of endothelin receptors mediating the effects of endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guinea-pig ileum. Br J Pharmacol 110:783–789.

    Article  PubMed  CAS  Google Scholar 

  35. Devadason PS, Henry PJ. 1997. Comparison of the contractile effects and binding kinetics of endothelin-1 and sarafotoxin S6b in rat isolated renal artery. Br J Pharmacol 121:253–263.

    Article  PubMed  CAS  Google Scholar 

  36. Nosaka C, Ishikawa H, Haruno I, Yoshitomi T, Kase H, Ishikawa S, Harada Y 1998. Radioligand binding characteristics of the endothelin receptor in the rabbit iris. Jpn J Pharmacol 76:289–296.

    Article  PubMed  CAS  Google Scholar 

  37. Douglas SA, Beck GRJ, Elliot JD, Ohlstein EH. 1995. Pharmacologic evidence for the presence of three functional endothelin receptor subtypes in rabbit saphenous vein. J Cardiovasc Pharmacol 26:S163–S168.

    PubMed  Google Scholar 

  38. Mizuguchi T, Nishiyama M, Moroi K, Tanaka H, Saito T, Masuda Y, Masaki T, de Wit D, Yanagisawa M, Kimura S. 1997. Analysis of two pharmacologically predicted endothelin B receptor subtypes by using the endothelin receptor B knockout mouse. Br J Pharmacol 120:1427–1430.

    Article  PubMed  CAS  Google Scholar 

  39. Blauw GJ, Westendorp RG, Srivistava N, Burggraaf K, Frolich M, Simons R, Cohen AF, Meinders AE. 1995. Hypoxia induced arterial endothelin does not influence peripheral vascular tone. J Cardiovasc Pharmacol 26[Suppl 3]:S242–S243.

    PubMed  CAS  Google Scholar 

  40. Karamazyn M. 1996. The role of endothelin in cardiac function in health and disease. In: Myocardial Ischemia, Mechanisms, Reperfusion, Protection. Karamazyn M (Ed.), pp. 209–230. Birkhauser, Basel, Switzerland.

    Chapter  Google Scholar 

  41. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415.

    Article  PubMed  CAS  Google Scholar 

  42. Emori T, Hirata Y, Imai T, Ohta K, Kanno K, Eguchi S, Marumo E 1992. Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell. Biochem Pharmacol 44:2409–2411.

    Article  PubMed  CAS  Google Scholar 

  43. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H, Yazaki Y. 1989. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 159:1435–1440.

    Article  PubMed  CAS  Google Scholar 

  44. Malek AM, Zhang J, Jiang J, Alper SL, Izumo S. 1999. Endothelin-1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. J Mol Cell Cardiol 31:387–399.

    Article  PubMed  CAS  Google Scholar 

  45. Yoshimoto S, Ishizaki Y, Sasaki T, Murota S. 1991. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 22:378–383.

    Article  PubMed  CAS  Google Scholar 

  46. Boulanger C, Luscher TE 1990. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85:587–590.

    Article  PubMed  CAS  Google Scholar 

  47. Prins BA, Hu RM, Nazario B, Pedram A, Frank HJ, Weber MA, Levin ER. 1994. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells.J Biol Chem 269:11938–11944.

    PubMed  CAS  Google Scholar 

  48. Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T. 1992. C-type natriuretic peptide inhibits thrombin-and angiotensin II-stimulated endothelin release via cyclic guanosine 3’,5’- monophosphate. Hypertension 19:320–325.

    Article  PubMed  CAS  Google Scholar 

  49. Okumura K, Nishiura T, Awaji Y, Kondo J, Hashimoto H, Ito T. 1991. 1,2-diacylglycerol content and its composition in thoracic aorta of diabetic rats. Diabetes 40:820–824.

    CAS  Google Scholar 

  50. Xia P, Inoguchi T, Kern KS, Engerman RL, Oats PJ, King GL. 1994. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C in diabetes and hypergalactosaemia. Diabetes 43:1122–1129.

    Article  PubMed  CAS  Google Scholar 

  51. Li W, Wang W, Liu X. 1994. Comparative study of high-glucose effect on phosphatidylcholine hydrolysis of cultured retinal capillary pericytes and endothelial cells, Biochem Biophys Acta 1222:339–347.

    Article  PubMed  CAS  Google Scholar 

  52. Chen S, Apostolova MD, Cherian MG, Chakrabarti S. 2000. Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells. Lab Invest 80:1311–1321.

    Article  PubMed  CAS  Google Scholar 

  53. King GL, Brownlee M. 1996. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 25:255–270.

    Article  PubMed  CAS  Google Scholar 

  54. Koya D, King GL. 1998. Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866.

    Article  PubMed  CAS  Google Scholar 

  55. Johannes FJ, Prestle J, Eis S, Oberhagemann P, Pfizenmaier K. 1994. PKC is a novel, atypical member of the protein kinase C family. J Biol Chem 269:6140–6148.

    PubMed  CAS  Google Scholar 

  56. Lynch JJ, Ferro TJ, Blumenstock FA, Brockenauer AM, Malik AB. 1990. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest 85:991–998.

    Article  Google Scholar 

  57. Williams B, Gallacher B, Patel H, Orme C. 1997. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 46:1497–1503.

    Article  PubMed  CAS  Google Scholar 

  58. Kern TS, Engerman RL. 1994. Comparison of retinal lesions in alloxan-diabetic rats and galactosefed rats. Curr Eye Res 13:863–867.

    Article  PubMed  CAS  Google Scholar 

  59. Kowluru RA, Kern TS, Engerman RL, Armstrong D. 1996. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 45:1233–1237.

    Article  PubMed  CAS  Google Scholar 

  60. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL. 1996. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728–731.

    Article  PubMed  CAS  Google Scholar 

  61. Williamson JR, Chang K, Frangos M, et al. 1993. Perspectives in Diabetes. Hyperglycemic pseudo-hypoxia and diabetic complications. Diabetes 42:801–813.

    Article  PubMed  CAS  Google Scholar 

  62. Costantino L, Rastelli G, Vianello P, Cignarella G, Barlocco D. 1999. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med Res Rev 19:3–23.

    Article  PubMed  CAS  Google Scholar 

  63. Engerman RL, Kern TS, Garment MB. 1993. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition. J Diabetes Complications 7:241–245.

    Article  PubMed  CAS  Google Scholar 

  64. Pugliese G, Tilton RG, Williamson JR. 1991. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 7:35–59.

    Article  PubMed  CAS  Google Scholar 

  65. Vlassara H. 1997. Recent progress in advanced glycation end products and diabetic complications. Diabetes 46(Suppl. 2):S19–S25.

    PubMed  CAS  Google Scholar 

  66. Vlassara H. 2001. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17:436–443.

    Article  PubMed  CAS  Google Scholar 

  67. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. 1998. AGEs and their interaction with AGE- receptors in vascular disease and diabetes mellitus I. The AGE concept. Cardiovasc Res 37:586–600.

    Article  PubMed  CAS  Google Scholar 

  68. Takagi Y, Kashiwagi A, Tanaka Y, Asahian T, Kikkawa R, Shigeta Y. 1995. Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabet Complications 9:89–91.

    Article  Google Scholar 

  69. Curcio F, Pegorano I, dello Russo P, Failed E, Perrilla G, Ceriello A. 1995. SOD and GSH inhibit the high glucose induced oxidative damage and the PDGF increase secretion in cultured endothelial cells. Thromb Haemost 74:969–973.

    PubMed  CAS  Google Scholar 

  70. Tesfamariam B, Cohen RA. 1992. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Phsyiol 263:H321–H326.

    CAS  Google Scholar 

  71. Ohishi K, Carmines PK. 1995. Superoxide dismutase restores the influence of nitric oxide on renal arterioles in diabetes mellitus. Am J Soc Nephrol 5:1559–1566.

    CAS  Google Scholar 

  72. Dileepan K, Sharma R, Stechschulte DJ, Savin VJ. 1993. Effect of superoxide exposure on albumin permeability of isolated rat glomeruli. J Lab Clin Med 121:797–804.

    PubMed  CAS  Google Scholar 

  73. Vasan S, Foiles PG, Founds HW. 2001. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 10:1977–1987.

    Article  PubMed  CAS  Google Scholar 

  74. Kern TS, Engerman RL. 2001. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 50:1636–1642.

    Article  PubMed  CAS  Google Scholar 

  75. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, Luther T, Berentshtein E, Tritschler H, Muller M.Wahl P, Ziegler R, Nawroth PP. 1997. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 46:1481–1490.

    Article  PubMed  CAS  Google Scholar 

  76. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W, Nawroth PP. 2000. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49:1561–1570.

    Article  PubMed  CAS  Google Scholar 

  77. Hattori Y, Banba N, Gross SS, Kasai K. 1999. Glycated serum albumin-induced nitric oxide production in vascular smooth muscle cells by nuclear factor kappaB-dependent transcriptional activation of inducible nitric oxide synthase. Biochem Biophys Res Commun 259:128–132.

    Article  PubMed  CAS  Google Scholar 

  78. Moncada S. 1992. The L-arginine/nitric oxide pathway. Acta Physiol Scand 145:201–227.

    Article  PubMed  CAS  Google Scholar 

  79. Bredt DS, Snyder SH. 1990. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87:682–685.

    Article  PubMed  CAS  Google Scholar 

  80. Moncada S, Palmer RMJ, Higgs EA. 1991. Nitric oxide, physiology, pathophysiology, and pharmacology. Pharm Rev 43:109–142.

    PubMed  CAS  Google Scholar 

  81. Nathan C. 1992. Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051–3064.

    PubMed  CAS  Google Scholar 

  82. Liiiischer TF. 1990. Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension? Am J Hypertens 3:317–330.

    Google Scholar 

  83. Cosentino F, Luscher TF. 2001. Effects of blood pressure and glucose on endothelial function. Curr Hypertens Rep 3:79–88.

    Article  PubMed  CAS  Google Scholar 

  84. Cosentino F, Luscher TF. 1998. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32(Suppl 3):S54–S61.

    Google Scholar 

  85. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. 1997. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96:25–28.

    Article  PubMed  CAS  Google Scholar 

  86. Van Dam B, Demirci C, Reitsma HJ, van Lambalgen, AA, van den Bos GC, Tangelder GJ, Stehouwer CD. 2000. Alterations in nitric oxide activity and sensitivity in early streptozotocin-induced diabetes depend on arteriolar size. Int J Exp Diabetes Res 1:221–232.

    Article  PubMed  Google Scholar 

  87. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW 1997. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34:55–68.

    Article  PubMed  CAS  Google Scholar 

  88. Hunt JV, Dean RT, Wolff SP. 1988. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 256:205–212.

    PubMed  CAS  Google Scholar 

  89. Nadler J, Winer L. 1996. Free radicals, nitric oxide and diabetic complications. In Diabetes Mellitus, LeRoith D, Taylor SI, Olefsky M (eds), pp. 840–848. Lippincott-Raven: Philadelphia.

    Google Scholar 

  90. Jiang ZY, Woollard AC, Wolff SP. 1990. Hydrogen peroxide production during experimental protein glycation. FEBS Lett 268:69–71.

    Article  PubMed  CAS  Google Scholar 

  91. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. 1998. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47:401–406.

    Article  PubMed  CAS  Google Scholar 

  92. Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. 1996. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 80:241–245.

    Article  PubMed  Google Scholar 

  93. Joussen AM, Huang S, Poulaki V, Camphausen K, Beecken WD, Kirchhof B, Adamis AP. 2001. In vivo retinal gene expression in early diabetes. Invest Ophthalmol Vis Sci 42:3047–3057.

    PubMed  CAS  Google Scholar 

  94. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. 2001. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12:993–1000.

    PubMed  Google Scholar 

  95. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LEH, King GL. 1997. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective (3-isoform-selective inhibitor. Diabetes 46:1473–1480.

    Article  PubMed  CAS  Google Scholar 

  96. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. 2001.VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408–2413.

    PubMed  CAS  Google Scholar 

  97. Cukiernik M, Hileeto D, Evans T, Mukherjee S, Downey D, Chakrabarti S. 2001. VEGF signal antagonism prevents early microvascular changes in the rat retina in diabetes. Canad. J Diabetes Care 25:192A.

    Google Scholar 

  98. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. 1989. vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309.

    Article  PubMed  CAS  Google Scholar 

  99. Tischer E, Gospodarowicz D, Mitchell R, Silva M, Schilling J, Lau K, Crisp T, Fiddes JC, Abraham JA. 1989. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 165:1198–1206.

    Article  PubMed  CAS  Google Scholar 

  100. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. 1991. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806–1814.

    Article  PubMed  CAS  Google Scholar 

  101. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. 1991. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947–11954.

    PubMed  CAS  Google Scholar 

  102. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta T. 1991. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 9:17–22.

    PubMed  CAS  Google Scholar 

  103. Rabelink TJ, Bakris GL. 1998. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab 24:381–388.

    Article  PubMed  CAS  Google Scholar 

  104. Moreau P, d’Uscio LV, Shaw S, Takase H, Barton M, Luscher TR 1997. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 96:1593–1597.

    Article  PubMed  CAS  Google Scholar 

  105. Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T, Quertermous T, King GL. 1991. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 266:23251–23256.

    PubMed  CAS  Google Scholar 

  106. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, Properzi G, Valesini G, De Mattia G, Santucci A. 1995. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 80:829–835.

    Article  PubMed  CAS  Google Scholar 

  107. Hopfner RL, Gopalakrishnan V. 1999. Endothelin: emerging role in diabetic vascular complications. Diabetologia 42:1383–1394.

    Article  PubMed  CAS  Google Scholar 

  108. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC. 2000. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 58:1534–1545.

    Article  PubMed  CAS  Google Scholar 

  109. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. 2000. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 32:1621–1629.

    Article  PubMed  CAS  Google Scholar 

  110. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S. 1999. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 42:1228–1234.

    Article  PubMed  CAS  Google Scholar 

  111. Chakravarthy U, Hayes RG, Stitt AW, Douglas A. 1997. Endothelin expression in ocular tissues of diabetic and insulin-treated rats. Invest Ophthalmol Vis Sci 38:2144–2151.

    PubMed  CAS  Google Scholar 

  112. Wu SQ, Tang F. 1998. Impaired paracrine effect of endothelin-1 on vascular smooth muscle in streptozotocin-diabetic rats. Cardiovasc Res 39:651–656.

    Article  PubMed  CAS  Google Scholar 

  113. Cameron NE, Dines KC, Cotter MA. 1994. The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats. Diabetologia 37:1209–1215.

    Article  PubMed  CAS  Google Scholar 

  114. Letizia C, Iannaccone A, Cerci S, Santi G, Cilli M, Coassin S, Pannarale MR, Scavo D, Iannacone A. 1997. Circulating endothelin-1 in non-insulin-dependent diabetic patients with retinopathy. Horm Metab Res 29:247–251.

    Article  PubMed  CAS  Google Scholar 

  115. Laurenti O, Vingolo EM, Desideri GB, Ferri C, Bellini C, Cassone-Faldetta M, Santucci A, De Mattia G. 1997. Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage. Exp Clin Endocrinol Diabetes 105(Suppl 2):40–42.

    Article  PubMed  CAS  Google Scholar 

  116. De Mattia G, Cassone-Faldetta M, Bellini C, Bravi MC, Laurenti O, Baldoncini R, Santucci A, Ferri C. 1998. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens 11:983–988.

    Article  PubMed  Google Scholar 

  117. Takahashi K, Ghatei MA, Lam HC, O’Halloran DJ, Bloom SR. 1990. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33:306–310.

    Article  PubMed  CAS  Google Scholar 

  118. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R. 1995. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 18:87–89.

    Article  PubMed  CAS  Google Scholar 

  119. Kawamura M, Ohgawara H, Naruse M, Suzuki N, Iwasaki N, Naruse K, Hori S, Demura H, Omori Y. 1992. Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care 15:1396–1397.

    Article  PubMed  CAS  Google Scholar 

  120. Donatelli M, Colletti I, Bucalo ML, Russo V, Verga S. 1994. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 25:159–164.

    PubMed  CAS  Google Scholar 

  121. Kamoi K, Ishibashi M, Yamaji T. 1994. Endothelin-1 and big endothelin-1 in NIDDM patients with and without microangiopathy. Diabetes Res Clin Pract 24:125–129.

    Article  PubMed  CAS  Google Scholar 

  122. Bertello P, Veglio F, Pinna G, Gurioli L, Molino P, Alban S, Chiandussi L. 1994. Plasma endothelin in NIDDM patients with and without complications. Diabetes Care 17:574–577.

    Article  PubMed  CAS  Google Scholar 

  123. Haak T, Jungmann E, Felber A, Hillmann U, Usadel KH. 1992. Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens 5:161–166.

    PubMed  CAS  Google Scholar 

  124. Rubanyi GM, Polokof MA. 1994. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacology Rev 46:326–414.

    Google Scholar 

  125. Levin ER. 1995. Endothelins, New Engl J Med 333:356–363.

    Article  PubMed  CAS  Google Scholar 

  126. Chakrabarti S, Cukiernik M, Mukherjee S, Chen S. 2000. Therapeutic potentials of endothelin receptor antagonists in diabetes. In: Monthly Focus: Oncologic, Endocrine & Motabolic in Exp Opin Invest Drugs 9(12):2873–2888.

    CAS  Google Scholar 

  127. Jorkasky DK, Hay DWP, Freed MI. 1995. The role of endothelin in human disease: implications and potential therapeutic intervention. In: Endothelin receptors: from the genes to the human. Ruffolo RR Jr. (Ed.), CRC, Boca Raton, FL, pp. 215–271.

    Google Scholar 

  128. Chen S, Mukherjee S, Chakrabarti S. 2001. Hyperglycemia induced, endothelin (ET) mediated, increased extracellular matrix (ECM) protein synthesis is mediated via NFKB activation. Diabetes 50(Suppl 2):A191.

    Google Scholar 

  129. Evans T, Deng DX, Chen S, Chakrabarti S. 2000. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 49:662–666.

    Article  PubMed  CAS  Google Scholar 

  130. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A. 2000. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157:1703–1711.

    Article  PubMed  CAS  Google Scholar 

  131. Bek EL, McMillen MA. 2000. Endothelins are angiogenic. J Cardiovasc Pharmacol 36(5 Suppl 1):S135–S139.

    PubMed  CAS  Google Scholar 

  132. Brennan PA, Zaki GA. 2000. Angiogenesis in cancer: the role of endothelin-1. Ann R Coll Surg Engl 82:363–364.

    PubMed  CAS  Google Scholar 

  133. Perfet F, Tarquini R, Tapparini L, Tarquini B. 1998. Influence of non-insulin-dependent diabetes mellitus on plasma endothelin-1 levels in patients with advanced atherosclerosis. J Diabetes Complications 12:187–192.

    Article  Google Scholar 

  134. Gilbert RE, Rumber JR, Cao ZM, Cox AJ, van Eeden P, Allen TJ, Kelly DJ, Cooper ME. 2000. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy and epidermal growth factor expression in experimental diabetes. Circ Res 86:158–165.

    Article  PubMed  CAS  Google Scholar 

  135. Makino A, Oda S, Kamata K. 2001. Mechanisms underlying increased release of endothelin-1 from aorta in diabetic rats. Peptides 22:639–645.

    Article  PubMed  CAS  Google Scholar 

  136. Makino A, Kamata K. 1998. Elevated plasma endothelin-1 levels in streptozotocin induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br J Pharmacol 123:1065–1072.

    Article  PubMed  CAS  Google Scholar 

  137. Takeda Y, Miyamori I, Yoneda T, Takeda R. 1991. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rat. Life Sci 48:2553–2556.

    Article  PubMed  CAS  Google Scholar 

  138. Migdalis IN, Kalogeropoulou K, Iliopoulou V, Triantafilou P, Charalabides J, Mortzos G, Cordopatis C. 2001. Plasma levels of endothelin, lipid peroxides and prostacyclin in diabetic patients with macroangiopathy. Diab Res Clin Prac 54:129–136.

    Article  CAS  Google Scholar 

  139. Taylor PD, Graves JE, Bakris GL. 1995. Selective impairment of acetylcholine-mediated endothelium-dependent relaxation in isolated resistance arteries of the streptozotocin-induced diabetic rat. Clin Sci 88:519–524.

    PubMed  CAS  Google Scholar 

  140. Suzuki T, Kumazaki T, Mitsui Y. 1993. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun 191:823–830.

    Article  PubMed  CAS  Google Scholar 

  141. Chua BH, Chua CC, Diglio CA, Siu BB. 1993. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochem Biophys Acta 1178:201–206.

    Article  PubMed  CAS  Google Scholar 

  142. Fukuchi M, Giaid A. 1998. Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts, J Cardiovasc Pharmacol. 31 (Suppl 1):S421–S423.

    Article  PubMed  CAS  Google Scholar 

  143. Vesci L, Mattera GG, Tobia P, Corsico N, Calvani M. 1995. Cardiac and renal endothelin-1 binding sites in streptozotocin-induced diabetic rats. Pharmacol Res 32:363–367.

    Article  PubMed  CAS  Google Scholar 

  144. Hu JR, von Harsdorf R, Lang RE. 1988. Endothelin has potent inotropic effects in rat atria. Eur J Pharmacol 158:275–278.

    Article  PubMed  CAS  Google Scholar 

  145. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. 1988. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. Pflugers Arch 413:108–110.

    Article  PubMed  CAS  Google Scholar 

  146. Lieu AT, Reid JJ. 1994. Changes in the responsiveness to endothelin-1 in isolated atria from diabetic rats. Eur J Pharmacol 261:33–42.

    Article  PubMed  CAS  Google Scholar 

  147. Erbas T, Erbas B, Kabakci G, Aksoyek S, Koray Z, Gedik O. 2000. Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus. Clin Cardiol 23:259–263.

    Article  PubMed  CAS  Google Scholar 

  148. Sharma AC, Fogelson BG, Nawas SI, Vigneswaran WT, Sam AD 2nd, Alden KJ, Ferguson JL, Law WR. 1999. Elevated coronary endothelin-1 but not nitric oxide in diabetics during CABG. Ann Thorac Surg 67:1659–1663.

    Article  PubMed  CAS  Google Scholar 

  149. Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K. 1999. The myocardial Na(+)-H(+) exchange: structure, regulation and its role in heart disease. Circ Res 85:777–786.

    Article  PubMed  CAS  Google Scholar 

  150. Lazdunski M, Frelin QVigne P. 1985. The sodium/hydrogen exchange system in cardiac cells: its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. J Mol Cell Cardiol 17:1029–1042.

    Article  PubMed  CAS  Google Scholar 

  151. Hileeto D, Cukiernik M, Evans T, Chen S, Mukherjee S, Downey D, Karmazyn M, Chakrabarti S. 2001. Interaction of endothelin-1 and sodium/hydrogen exchanger-1 in the pathogenesis of diabetes induced changes in the heart. Diabetes 50(Suppl 2):Al 55.

    Google Scholar 

  152. Vanhoutte PM. 1994. Endothelin-1. A matter of life and breath. Nature 368:693–694.

    Article  PubMed  CAS  Google Scholar 

  153. Pedram A, Razandi M, Hu RM, Levin ER. (1997). Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 27:17097–17103.

    Article  Google Scholar 

  154. Matsuura A, Kawashima S, Yamochi W, Hirata K, Yamaguchi T, Emoto N, Yokoyama M. 1997. Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells. Biochem Biophys Res Commun 235:713–716.

    Article  PubMed  CAS  Google Scholar 

  155. Mukherjee S, Evans T, Chen S, Cukiernik M, Hileeto D, Karmazyn M, Chakrabarti S. 2001. Nitric Oxide in diabetic hearts. Canadian Journal of Diabetes Care 25:192.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of pathology, The University of Western Ontario, London, Ontario, Canada

    Subrata Chakrabarti

Authors
  1. Subrata Chakrabarti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Stroke & Vascular Disease, St. Boniface General Hospital Research Centre, Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Grant N. Pierce PhD, FACC (Professor & Director) (Professor & Director)

  2. Department of Medicine, Jikei University School of Medicine, Tokyo, Japan

    Makoto Nagano MD, PhD (Professor Emeritus) (Professor Emeritus)

  3. Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Peter Zahradka PhD (Associate Professor) & Naranjan S. Dhalla PhD, MD (Hon), DSc (Hon) (Distinguished Professor and Director) (Associate Professor) &  (Distinguished Professor and Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Chakrabarti, S. (2003). Endothelins and Cardiovascular Disease in Diabetes. In: Pierce, G.N., Nagano, M., Zahradka, P., Dhalla, N.S. (eds) Atherosclerosis, Hypertension and Diabetes. Progress in Experimental Cardiology, vol 8. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9232-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9232-1_24

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4850-4

  • Online ISBN: 978-1-4419-9232-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation